Mesoblast (MESO) Finished Goods (2024 - 2026)
Mesoblast (MESO) posted Finished Goods of $15.6 million for Q4 2025, down 26.58% sequentially from $21.2 million in Q2 2025, and down 33.1% YoY from $23.2 million in Q4 2024.
Powered by 
Analysis
Mesoblast (MESO) Finished Goods (2024 - 2026) Analysis & Trends
Mesoblast has reported Finished Goods for 2 years, with the latest figure at $15.6 million in Q4 2025.
- Quarterly Finished Goods fell 33.1% year-over-year to $15.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.6 million (down 33.1% YoY) and the FY2025 annual result came in at $21.2 million, changed N/A from the prior year.
- Finished Goods slipped to $15.6 million in Q4 2025 per MESO's latest filing, from $21.2 million in the prior quarter.
- Over five years, Finished Goods peaked at $23.2 million in Q4 2024 and troughed at $15.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.62 Mn |
| Dec 31, 2025 | 15.55 Mn |
| Jun 30, 2025 | 21.18 Mn |
| Dec 31, 2024 | 23.25 Mn |